Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad35.RSV.FA2 and Ad26.RSV.FA2 prime-boost in healthy adults
NCT02440035Phase 1Completed
- Sponsor
- Crucell
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ad35.rsv.fa2 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Crucell. Primary endpoints: Solicited Local and Systemic Adverse Events, Unsolicited Adverse Events and 1 more. Started Apr 2015; status: completed.
02
Drugs
ad35.rsv.fa2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02440035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440035.